高钠血症 中国就医指南

Hypernatremia is a potentially life-threatening electrolyte disorder characterized by an elevated serum sodium concentration exceeding 145 mmol/L. It reflects a relative deficit of total body water compared to total body sodium—most commonly due to water loss (e.g., from inadequate intake, osmotic diuresis, gastrointestinal losses, or insensible losses) rather than sodium excess. Pathophysiologically, hypernatremia triggers cellular dehydration, especially in the central nervous system, leading to neuronal shrinkage, disruption of synaptic transmission, and increased risk of intracranial hemorrhage or venous thrombosis upon rapid correction. The hypothalamic thirst mechanism and arginine vasopressin (AVP) axis are critical regulators; impairment in either—due to aging, neurologic injury, dementia, or institutionalization—significantly increases susceptibility. Epidemiologically, hypernatremia is relatively uncommon in the general population (<0.1%) but highly prevalent in vulnerable clinical settings: it affects 1–2% of hospitalized adults, up to 10–20% of critically ill ICU patients, and over 30% of elderly residents in long-term care facilities. Incidence rises sharply with age, particularly among those over 65 years, and is strongly associated with functional dependence, impaired cognition, and limited access to fluids. Key risk factors include diabetes insipidus (central or nephrogenic), severe diarrhea or vomiting, diuretic use (especially thiazides), hypertonic IV fluid administration, burns, fever, mechanical ventilation, and medications that impair thirst or AVP release (e.g., lithium, demeclocycline). Importantly, iatrogenic causes—such as inappropriate administration of hypertonic saline or sodium bicarbonate—are increasingly recognized contributors. Quality of life impact is profound: even mild-to-moderate hypernatremia correlates with increased fatigue, confusion, irritability, muscle weakness, and gait instability—symptoms often misattributed to aging or dementia. Severe cases (>155 mmol/L) may cause seizures, coma, or permanent neurologic deficits. Survivors frequently experience prolonged cognitive impairment, reduced mobility, higher rates of institutionalization, and diminished independence in activities of daily living. Mortality escalates markedly with severity and speed of onset: acute hypernatremia carries a mortality rate of 20–60%, while chronic cases still confer 10–40% mortality—largely attributable to underlying comorbidities and complications of both the disorder and its correction. Early recognition, careful assessment of volume status (hypovolemic, euvolemic, or hypervolemic), and individualized, gradual rehydration remain cornerstones of management to prevent cerebral edema and osmotic demyelination syndrome.

# 高钠血症（内分泌科）治疗方案与费用明细

一、非手术/保守治疗方案

适用人群：轻中度（血钠145–159 mmol/L）、无意识障碍、肾功能稳定者。

• •口服补液+限钠管理：个体化低钠饮食指导+口服葡萄糖电解质溶液，300–800元/疗程（7天）
• •静脉补液（0.45%氯化钠或5%葡萄糖）：含电解质监测（每日血钠、渗透压、尿量），1200–2500元/疗程（3–5天）
• •检查费：血钠/钾/氯/渗透压/尿钠/肾功能/血糖/皮质醇（ACTH刺激试验如需），680–1150元/次

二、药物干预方案

适用人群：中枢性尿崩症继发高钠、ADH抵抗型患者。

• •去氨加压素（鼻喷/口服）：国产仿制药（如弥凝®），420–960元/月；原研药1800–3200元/月
• •噻嗪类利尿剂（氢氯噻嗪）联合补钾：用于部分性尿崩症，35–120元/月

三、核心介入/重症监护方案

适用人群：重度（血钠≥160 mmol/L）、昏迷、抽搐、急性肾损伤者。

• •ICU内可控降钠（≤0.5 mmol/L/h）+连续性肾脏替代治疗（CRRT）：含中心静脉置管、血流动力学监测、神经功能评估，18,000–35,000元/日
• •术前/术中检查费（含头颅MRI、垂体动态增强、血浆AVP测定）：2,400–4,800元/次

四、特殊复杂方案

适用人群：顽固性高钠合并垂体卒中、严重下丘脑损伤、医源性渗透性脱髓鞘风险者。

• •多学科MDT（内分泌+神经内科+重症医学）全程管理，8,000–15,000元/周；含神经电生理监测及渗透压梯度调控

方案快速选择指南

• •预算＜2000元/次：门诊口服补液+基础检验（首选）
• •预算5000–15000元：住院静脉补液+激素评估（覆盖90%病因）
• •危重/昏迷患者：立即转入ICU启动CRRT+多学科干预（不可延迟）